Ramucirumab
Ramucirumab Basic information
- Product Name:
- Ramucirumab
- Synonyms:
-
- Ramucirumab
- Ramucirumab,NSCLC,non–small-cell lung cancer,gastric cancer,Inhibitor,VEGFR,Vascular endothelial growth factor receptor,inhibit,angiogenesis inhibitor
- Cyramza
- IMC-1121B
- LY3009806
- Ramucirumab (anti-VEGFR2)
- CAS:
- 947687-13-0
- MW:
- 0
- Mol File:
- Mol File
More
Less
Ramucirumab Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
More
Less
Safety Information
- Hazardous Substances Data
- 947687-13-0(Hazardous Substances Data)
More
Less
Ramucirumab Usage And Synthesis
Clinical Use
Human monoclonal antibody:
Treatment of advanced gastric cancer or gastrooesophageal junction adenocarcinoma, colorectal
cancer and non-small cell lung cancer (NSLC)
target
VEGFR2
Drug interactions
Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid.
Metabolism
The metabolism of ramucirumab has not been studied. Monoclonal antibodies are mainly cleared by catabolism.
RamucirumabSupplier
Wuhan Fortuna Chemical Co., Ltd
- Tel
- 027-027-59207852 13308628970
- buy@fortunachem.com
Dalian Meilun Biotech Co., Ltd.
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
Sichuan Wei Keqi Biological Technology Co., Ltd.
- Tel
- 028-81700200 18116577057
- 3003855609@qq.com
Taizhou KEDE Chemical Co., Ltd
- Tel
- 0576-84613060 13093829633
- sales@kedechemical.com
Shanghai Lollane Biological Technology Co.,Ltd.
- Tel
- 021-52996696，15000506266 15000506266
More
Less
Ramucirumab(947687-13-0)Related Product Information
- Adalimumab
- Ustekinumab
- Nivolumab
- Bevacizumab
- Daratumumab
- OMALIZUMAB
- Lambrolizumab
- Dulaglutide
- Infliximab
- Rituximab
- palivizumab
- Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
- Atezolizumab
- Denosumab
- CETUXIMAB
- Evolocumab
- ipilimumab
- Eculizumab